Navigation Links
Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
Date:12/13/2010

l allow us to expedite the initiation of the Phase 3 trial, since we will no longer have to halt enrollment after 60 patients are accrued to the trial to allow the DSMB to review safety data. We will be able to complete the Phase 1 study at the same time the required 13-week animal toxicology studies are being conducted and while the Phase 3 clinical trial material is manufactured and packaged," concluded Dr. Tagliaferri.

We anticipate starting the Phase 1 study in Q1, 2011 and beginning the Phase 3A pivotal trial in Q2, 2011.

"We are excited to move Menerba forward in the path to commercialization. Menerba is an important new treatment approach for millions of women suffering from menopausal hot flashes", said Isaac Cohen, O.M.D., Chairman and CEO of Bionovo. "The discussion with the FDA was also fruitful concerning future potential labeling of Menerba. Bionovo provided additional data to support our claim that Menerba is not an estrogen and not a SERM. The FDA acknowledged that Menerba is a selective estrogen receptor beta agonist. Granted we continue to show no safety concerns after the Phase 3 trials, Menerba will provide a safer alternative to current hormone therapy."

About Menerba

Menerba is an oral botanical drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with activation of estrogen receptor alpha (ER-a) and that activation of estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. The active ingredients in Menerba are derived from botanicals with centuries of recorded safe, effective use in traditional Chinese medicine (TCM). B
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle ... makers of medical devices. As part of its ... in EMEA concentrates on the EMEA medical device ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8
... Aug. 25, 2011 BioRestorative Therapies, Inc. ... into a Tangible Property License Agreement with the University ... Therapies to obtain adipose (fat) tissue that will be ... ThermoStem Program , which is an adult derived ...
... ePharmaSolutions announced the successful deployment of its Enterprise ... global pharmaceutical company on more than 900 studies to ... September 2011. Clinical Trial Portals help streamline ... sites and third party vendors by providing a common ...
Cached Medicine Technology:BioRestorative Therapies Signs License Agreement With University of Utah to Obtain Adipose (Fat) Tissue for its ThermoStem Program to Treat Obesity and Metabolic Disorders 2ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies 2
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... NEW YORK -- The most common cause of endophthalmitis, ... trauma, eye surgery, and eye injections, are the well-known ... bacterial strains, according to a study published in the ... a review of 25 years of cases at New ... , The new study found that gram-positive bacteria, ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, 2014 ... baby,s immune system is twice as common as once believed, ... This is the first evaluation of the effect of ... severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the researchers ... the boy in the bubble, who was born without an ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... similar results, , , WEDNESDAY, Feb. 25 (HealthDay News) -- If ... type of diet plan you choose. What really matters is that ... 26 issue of the New England Journal of Medicine ... of fat, protein and carbohydrates -- and found that any eating ...
... Millstone Medical Outsourcing announced today the opening of ... The company acquired the new 30,000 square foot facility ... and clean room services. The company will continue ... foreseeable future. In addition to the two Fall ...
... hormones, not HRT, researchers note , , WEDNESDAY, Feb. 25 ... help protect her from developing Parkinson,s disease, a new ... (the time from first menstruation to menopause) have a ... findings released Wednesday and scheduled to be presented at ...
... Other Health Insurers Illegally Deny Treatment to Autistic Children, ... of autistic children and their families joined Consumer Watchdog ... health insurance companies that are scheming to avoid paying ... , , Consumer Watchdog released a letter ...
... United Airlines customer service representatives, ramp employees, flight ... at Children,s Memorial Hospital and University of ... United Airlines employees today delivered teddy bears to ... and University of Chicago Comer Children,s ...
... to ,Protect the Safety Net, , WASHINGTON, Feb. 25 ... long-term care advocacy organizations, the American Health Care Association ... today praised and thanked U.S. Representatives Earl Pomeroy (D-ND), ... Brown-Waite (R-FL) for sending a new letter to President ...
Cached Medicine News:Health News:Want to Lose Weight? Just Eat Less, Diet Study Suggests 2Health News:Want to Lose Weight? Just Eat Less, Diet Study Suggests 3Health News:Millstone Medical Outsourcing Opens New Facility to Provide Additional Capacity for Advanced Inspection, Clean Room Operations 2Health News:Hormones May Help Shield Women from Parkinson's 2Health News:Parents of Autistic Children Fight Back -- Warn HMO Regulator Against Siding With Insurers Refusing to Pay for Treatment 2Health News:Parents of Autistic Children Fight Back -- Warn HMO Regulator Against Siding With Insurers Refusing to Pay for Treatment 3Health News:Delivering Bear-y Big Smiles and Millions of Miles 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: